Drug Trial Radar · NCT00244244
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
Last checked: Nov 19, 2026Latest source record: Feb 9, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Oct 2005
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- CytRxIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
arimoclomolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine Medical Center
Irvine, California
University of Miami School of Medicine
Miami, Florida
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Hennepin Faculty Associates/Berman Center
Minneapolis, Minnesota
SUNY Upstate Medical University
Syracuse, New York
Duke University
Durham, North Carolina
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.